1,432 results on '"Leishmaniasis, Mucocutaneous"'
Search Results
2. Co-circulation of 'Leishmania' parasites and phleboviruses in a population of sand flies collected in the south of Portugal
- Author
-
Amaro, Fatima, Vilares, Anabela, Martins, Susana, Reis, Tania, Osorio, Hugo Costa, Alves, Maria Joao, and Gargate, Maria Joao
- Published
- 2024
3. Treatment of Bolivian L Braziliensis Mucosal Leishmaniasis With Inhaled Pentamidine Plus Oral Miltefosine
- Author
-
Jaime Soto, Head
- Published
- 2024
4. Treatment of Mucosal Bolivian Leishmaniasis
- Author
-
Hospital Dermatologico de Jorochito, Centro Nacional de Enfermedades Tropicales CENETROP, and ABF Foundation for Medical Research
- Published
- 2024
5. Compassionate Use of Sodium Stibogluconate (Pentostam) for Cutaneous and Mucocutaneous New World Leishmaniasis
- Published
- 2023
6. Pilot Study: Oral Treatment of American Tegumentary Leishmaniasis (Cutaneous and Mucosal Forms) in the Elderly
- Published
- 2023
7. Miltefosine to Treat Mucocutaneous Leishmaniasis
- Published
- 2020
8. Dedicated QT Study in Bolivian Patients Taking Impavido® (Miltefosine) for Mucocutaneous Leishmaniasis
- Published
- 2020
9. Spermiogram Assessment in Bolivian Patients Taking Impavido® (Miltefosine) for Mucocutaneous Leishmaniasis
- Published
- 2019
10. Low Antimonial Dosage in American Mucosal Leishmaniasis
- Author
-
Rio de Janeiro State Research Supporting Foundation (FAPERJ), Conselho Nacional de Desenvolvimento Científico e Tecnológico, and ASchubach, Senior Researcher
- Published
- 2018
11. Clinical and epidemiological aspects of American cutaneous leishmaniasis with genital involvement
- Author
-
Marcelo Rosandiski Lyra, Alan Bittencourt da Silva, Cláudia Maria Valete-Rosalino, and Maria Inês Fernandes Pimentel
- Subjects
Genital diseases, male ,Leishmania braziliensis ,Leishmaniasis, cutaneous ,Leishmaniasis, mucocutaneous ,Dermatology ,RL1-803 - Abstract
Abstract Genital lesions are an unusual presentation of American cutaneous leishmaniasis. Conditions such as disseminated cutaneous leishmaniasis and HIV infection may be associated with genital involvement. The authors present five cases of American cutaneous leishmaniasis with genital lesions and discuss the clinical and epidemiological aspects observed in this case series.
- Published
- 2020
- Full Text
- View/download PDF
12. A review on potential therapeutic targets for the treatment of leishmaniasis.
- Author
-
Sheikh SY, Hassan F, Shukla D, Bala S, Faruqui T, Akhter Y, Khan AR, and Nasibullah M
- Subjects
- Animals, Asia, Leishmaniasis drug therapy, Leishmania, Leishmaniasis, Visceral drug therapy, Leishmaniasis, Visceral parasitology, Leishmaniasis, Cutaneous, Leishmaniasis, Mucocutaneous, Leishmania donovani
- Abstract
Leishmania, a protozoan parasite, is responsible for the occurrence of leishmaniasis, a disease that is prevalent in tropical regions. Visceral Leishmaniasis (VL), also known as kala-azar in Asian countries, is one of the most significant forms of VL, along with Cutaneous Leishmaniasis (CL) and Mucocutaneous Leishmaniasis (ML). Management of this condition typically entails the use of chemotherapy as the sole therapeutic option. The current treatments for leishmaniasis present several drawbacks, including a multitude of side effects, prolonged treatment duration, disparate efficacy across different regions, and the emergence of resistance. To address this urgent need, it is imperative to identify alternative treatments that are both safer and more effective. The identification of appropriate pharmacological targets in conjunction with biological pathways constitutes the initial stage of drug discovery. In this review, we have addressed the key metabolic pathways that represent potential pharmacological targets as well as prominent treatment options for leishmaniasis., Competing Interests: Declaration of competing interest The authors declare no conflicts of interest., (Copyright © 2024. Published by Elsevier B.V.)
- Published
- 2024
- Full Text
- View/download PDF
13. Mucosal leishmaniasis: A forgotten disease, description and identification of species in 50 Colombian cases
- Author
-
Sandra Muvdi-Arenas and Clemencia Ovalle-Bracho
- Subjects
Leishmania ,leishmaniasis, mucocutaneous ,molecular typing ,polymerase chain reaction ,Medicine ,Arctic medicine. Tropical medicine ,RC955-962 - Abstract
Introduction: Mucosal leishmaniasis has a progressive course and can cause deformity and even mutilation in the affected areas. It is endemic in the American continent and it is mainly caused by Leishmania (Viannia) braziliensis. Objective: To describe a series of mucosal leishmaniasis cases and the infectious Leishmania species. Materials and methods: We included 50 patients with a clinical diagnosis of mucosal leishmaniasis and parasitological confirmation, and we described their clinical and laboratory results. We performed species typing by PCR-RFLP using the miniexon sequence and hsp70 genes; confirmation was done by sequencing. Results: The median time of disease evolution was 2.9 years (range: 1 month to 16 years). The relevant clinical findings included mucosal infiltration (94%), cutaneous leishmaniasis scar (74%), total loss of the nasal septum (24%), nasal deformity (22%), and mucosal ulceration (38%). The symptoms reported included nasal obstruction (90%), epistaxis (72%), rhinorrhea (72%), dysphonia (28%), dysphagia (18%), and nasal pruritus (34%). The histopathological study revealed a pattern compatible with leishmaniasis in 86% of the biopsies, and amastigotes were identified in 14% of them. The Montenegro skin test was positive in 86% of patients, immunofluorescence in 84%, and culture in 8%. Leishmania (V.) braziliensis was identified in 88% of the samples, L. (V) panamensis in 8%, and L. (V.) guyanensis and L. (L.) amazonensis in 2% respectively. Conclusion: In this study, we found a severe nasal disease with destruction and deformity of the nasal septum in 25% of the cases, probably associated with late diagnosis. Leishmania (V.) braziliensis was the predominant species. We described a case of mucosal leishmaniasis in Colombia caused by L. (L.) amazonensis for the first time.
- Published
- 2019
- Full Text
- View/download PDF
14. Profile of skin diseases in a community of fishermen in the northern coast of the state of São Paulo: the expected and the unusual
- Author
-
Vidal Haddad Junior
- Subjects
Animals, venomous ,Bacterial infections ,Bites and stings ,Fishing industry ,Folliculitis ,Leishmaniasis, mucocutaneous ,Skin diseases ,Solar radiation ,Dermatology ,RL1-803 - Abstract
Abstract: Background: The fishing colony of the Picinguaba neighborhood is located at the northern end of the coast of the state of São Paulo. It has about 300 residents, of which approximately 100 are professional fishermen. Objectives: This study aimed to identify the main dermatoses of the community in comparison with other populations, and their frequency. Methods: The dermatoses were identified and tabulated for two years, in a prospective study carried out on monthly trips to the fishermen’s colony in Picinguaba. Results: One hundred and eighteen patients were attended and followed up, which is equivalent to about 1/3 of the colony’s inhabitants. Of these, 43 were children (under the age of 14) and 75 were adolescents and adults. The diseases observed were catalogued according to the age groups. Although most dermatoses in the community were similar with those observed in the general population, some specific cases could be seen, such as folliculitis on the legs of fishermen and an unexpected low frequency of actinic lesions in the colony, as well as dermatitis by aquatic animals. Study Limitations: The limitations were monthly attendance and the spontaneous demand of the patients. Conclusions: The finding of community-specific dermatoses and the low incidence of malignant and pre-malignant tumors associated with sun exposure needs further studies for better clarification.
- Published
- 2019
- Full Text
- View/download PDF
15. Clinical Trial of Miltefosine to Treat Mucosal Leishmaniasis
- Author
-
Juliana Silva, Dr. Juliana Silva
- Published
- 2015
16. Clinical pattern and treatment outcome of Cutaneous Leishmaniasis in two hospitals in Bahir Dar, Ethiopia (2017-2021)
- Author
-
Tesfa, Debas, Manaye, Nigus, de Vries, Henry Jc, van Griensven, Johan, Enbiale, Wendemagegn, Dermatology, AII - Infectious diseases, and APH - Methodology
- Subjects
Leishmaniasis, Mucocutaneous ,Male ,DCL ,Leishmaniasis, Cutaneous ,LCL ,operational research ,General Medicine ,Microbiology ,Hospitals ,Treatment Outcome ,Infectious Diseases ,Addis Alem Hospital ,SORT IT ,Virology ,MCL treatment ,Humans ,Female ,Parasitology ,Ethiopia - Abstract
Introduction: Cutaneous Leishmaniasis (CL) in Ethiopia is caused by a unique species, L. aethiopica. In Ethiopia, there are limited studies that provide detailed clinical descriptions of CL, treatment options, and treatment outcomes. Methodology: We conducted a descriptive study based on routinely collected data in medical files from two hospitals in Bahir Dar, Ethiopia, from 2017 to 2021. Three months following the end of therapy, we retrieved sociodemographic and clinical data, as well as data on the treatment outcome. Result: Between March 2017 and June 2021, 94 patients were diagnosed with CL at the two hospitals. Of those, 46 (48.9%) of individuals had localized CL, 36 (38.3%) mucocutaneous leishmaniasis (MCL), and 12 (12.8%) diffuse CL. Sixty-five (69.1%) of the participants were men. The most prevalent morphologic appearances were plaque (n = 42, 46.2%), nodule (n = 38, 41.8%), infiltrative (n = 34, 36.2%), crusted (n = 32, 34%), and ulcerated (n = 24, 25.5%). Scarred, volcanic, and patchy lesions were also documented. Systemic pentavalent antimonials were the most common treatment (n = 55, 58.5%), curing 21/38 (55%) of the patients. Pentavalent antimonials were also given intralesionally to seventeen patients (18.1%), with 15/16 (94%) of them being cured. Overall, 61% (40/66) of patients with documented treatment outcomes were cured. Conclusions: As CL in Ethiopia has a wide array of clinical presentations, clinicians should be suspicious of patients from endemic areas who present with dermatologic manifestations. Physicians can employ local treatment as a first line before resorting to systemic therapy.
- Published
- 2022
17. The changing epidemiology of human leishmaniasis in the non-endemic country of Austria between 2000 to 2021, including a congenital case.
- Author
-
Riebenbauer K, Czerny S, Egg M, Urban N, Kinaciyan T, Hampel A, Fidelsberger L, Karlhofer F, Porkert S, Walochnik J, and Handisurya A
- Subjects
- Animals, Child, Humans, Austria epidemiology, Skin, Leishmania genetics, Leishmaniasis epidemiology, Leishmaniasis, Cutaneous epidemiology, Leishmaniasis, Mucocutaneous, Leishmaniasis, Visceral epidemiology, Psychodidae
- Abstract
Background: Leishmaniasis is caused by infection with intracellular protozoans of the genus Leishmania. Transmission occurs predominantly by the bite of phlebotomine sandflies, other routes, including congenital transmission, are rare. The disease manifests as either cutaneous, visceral or mucosal/mucocutaneous leishmaniasis. In recent years, changes in the epidemiological pattern have been reported from Europe., Principal Findings: A total of 311 new and 29 published leishmaniasis cases occurring between 01/01/2000 and 12/31/2021 in Austria were collected and analyzed. These encompassed 146 cutaneous (CL), 14 visceral (VL), 4 mucosal, and 3 cases with concurrent VL and CL. In addition, asymptomatic infections, comprising 11 unspecified cases with Leishmania DNA detectable only in the blood and 162 cases with anti-Leishmania antibodies were reported. Particularly since 2016, the incidence of leishmaniasis has steadily risen, mainly attributable to increasing numbers of CL and cases with positive serology against Leishmania species, whereas the incidence of VL has slowly decreased. Analysis revealed that a shift in the causative species spectrum had occurred and that a substantial number of CL cases were caused by members of the Leishmania donovani/infantum complex. Simultaneous occurrence of VL and CL was identified in immunocompromised individuals, but also in a not yet reported case of an immunocompetent child after vertical transmission., Conclusions: The incidence of leishmaniasis has risen in the recent years. The numbers are anticipated to keep rising due to increasing human mobility, including travel and forced migration, growing reservoir host populations as well as expansion and dispersal of vector species caused by climate and habitat changes, urbanization and globalization. Hence, elevated awareness for the disease, including possible transmission in previously non-endemic regions and non-vector transmission modes, support of sandfly surveillance efforts and implementation and establishment of public health interventions in a One Health approach are pivotal in the global efforts to control and reduce leishmaniasis., Competing Interests: The authors have declared that no competing interests exist., (Copyright: © 2024 Riebenbauer et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
- Published
- 2024
- Full Text
- View/download PDF
18. Stigma associated with cutaneous and mucocutaneous leishmaniasis: A systematic review.
- Author
-
Nuwangi H, Agampodi TC, Price HP, Shepherd T, Weerakoon KG, and Agampodi SB
- Subjects
- Humans, Cicatrix, Social Stigma, Stereotyping, Fear, Leishmaniasis, Mucocutaneous, Leishmaniasis, Cutaneous psychology
- Abstract
Background: Cutaneous (CL) and mucocutaneous leishmaniasis (MCL) are parasitic diseases caused by parasites of the genus leishmania leading to stigma caused by disfigurations. This study aimed to systematically review the dimensions, measurement methods, implications, and potential interventions done to reduce the CL- and MCL- associated stigma, synthesising the current evidence according to an accepted stigma framework., Methods: This systematic review followed the PRISMA guidelines and was registered in PROSPERO (ID- CRD42021274925). The eligibility criteria included primary articles discussing stigma associated with CL and MCL published in English, Spanish, or Portuguese up to January 2023. An electronic search was conducted in Medline, Embase, Scopus, PubMed, EBSCO, Web of Science, Global Index Medicus, Trip, and Cochrane Library. The mixed methods appraisal tool (MMAT) was used for quality checking. A narrative synthesis was conducted to summarise the findings., Results: A total of 16 studies were included. The studies report the cognitive, affective, and behavioural reactions associated with public stigma. Cognitive reactions included misbeliefs about the disease transmission and treatment, and death. Affective reactions encompass emotions like disgust and shame, often triggered by the presence of scars. Behavioural reactions included avoidance, discrimination, rejection, mockery, and disruptions of interpersonal relationships. The review also highlights self-stigma manifestations, including enacted, internalised, and felt stigma. Enacted stigma manifested as barriers to forming proper interpersonal relationships, avoidance, isolation, and perceiving CL lesions/scars as marks of shame. Felt stigma led to experiences of marginalisation, rejection, mockery, disruptions of interpersonal relationships, the anticipation of discrimination, fear of social stigmatisation, and facing disgust. Internalised stigma affected self-identity and caused psychological distress., Conclusions: There are various manifestations of stigma associated with CL and MCL. This review highlights the lack of knowledge on the structural stigma associated with CL, the lack of stigma interventions and the need for a unique stigma tool to measure stigma associated with CL and MCL., Competing Interests: The authors have declared that no competing interests exist., (Copyright: © 2023 Nuwangi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
- Published
- 2023
- Full Text
- View/download PDF
19. An unusual case of non-resolving lymphadenopathy due to New World leishmaniasis.
- Author
-
Finkelstain A, Schwartz E, and Lachish T
- Subjects
- Humans, Male, Adult, Leishmania braziliensis, Leishmaniasis, Cutaneous, Leishmaniasis, Mucocutaneous, Lymphadenopathy etiology
- Published
- 2023
- Full Text
- View/download PDF
20. Mucosal leishmaniasis: a forgotten disease. Description and identification of species in 50 Colombian cases.
- Author
-
Muvdi-Arenas, Sandra and Ovalle-Bracho, Clemencia
- Subjects
ITCHING ,LEISHMANIASIS ,NOSEBLEED ,CUTANEOUS leishmaniasis ,NASAL septum ,NASAL mucosa ,MUCOCUTANEOUS leishmaniasis - Abstract
Copyright of Biomédica: Revista del Instituto Nacional de Salud is the property of Instituto Nacional de Salud of Colombia and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2019
21. Study to Evaluate the Leish-111F + MPL-SE Vaccine in the Treatment of Mucosal Leishmaniasis
- Author
-
Bill and Melinda Gates Foundation
- Published
- 2007
22. Accuracy of mucocutaneous leishmaniasis diagnosis using polymerase chain reaction: systematic literature review and meta-analysis
- Author
-
Ciro Martins Gomes, Suleimy Cristina Mazin, Elisa Raphael dos Santos, Mariana Vicente Cesetti, Guilherme Albergaria Brízida Bächtold, João Henrique de Freitas Cordeiro, Fabrício Claudino Estrela Terra Theodoro, Fabiana dos Santos Damasco, Sebastián Andrés Vernal Carranza, Adriana de Oliveira Santos, Ana Maria Roselino, and Raimunda Nonata Ribeiro Sampaio
- Subjects
leishmaniasis, mucocutaneous ,diagnosis ,polymerase chain reaction ,Microbiology ,QR1-502 ,Infectious and parasitic diseases ,RC109-216 - Abstract
The diagnosis of mucocutaneous leishmaniasis (MCL) is hampered by the absence of a gold standard. An accurate diagnosis is essential because of the high toxicity of the medications for the disease. This study aimed to assess the ability of polymerase chain reaction (PCR) to identify MCL and to compare these results with clinical research recently published by the authors. A systematic literature review based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA Statement was performed using comprehensive search criteria and communication with the authors. A meta-analysis considering the estimates of the univariate and bivariate models was performed. Specificity near 100% was common among the papers. The primary reason for accuracy differences was sensitivity. The meta-analysis, which was only possible for PCR samples of lesion fragments, revealed a sensitivity of 71% [95% confidence interval (CI) = 0.59; 0.81] and a specificity of 93% (95% CI = 0.83; 0.98) in the bivariate model. The search for measures that could increase the sensitivity of PCR should be encouraged. The quality of the collected material and the optimisation of the amplification of genetic material should be prioritised.
- Published
- 2015
- Full Text
- View/download PDF
23. Co-expression analysis of lncRNA and mRNA suggests a role for ncRNA-mediated regulation of host-parasite interactions in primary skin lesions of patients with American tegumentary leishmaniasis.
- Author
-
Almeida MC, Felix JS, Lopes MFDS, de Athayde FRF, Troiano JA, Scaramele NF, Furlan AO, and Lopes FL
- Subjects
- Humans, Host-Parasite Interactions genetics, RNA, Messenger genetics, Disease Progression, RNA, Long Noncoding genetics, Leishmaniasis, Cutaneous parasitology, Leishmaniasis, Mucocutaneous, Leishmania genetics, Leishmania braziliensis genetics
- Abstract
Leishmaniasis, caused by different Leishmania species, manifests as cutaneous or visceral forms. In the American continent, the cutaneous form is called American tegumentary leishmaniasis (ATL) and is primarily caused by Leishmania (Viannia) braziliensis. Mucosal leishmaniasis (ML), the most severe form of ATL, arises in approximately 20% of patients from a primary cutaneous lesion. Evidence indicates changes in overall expression patterns of mRNAs and lncRNAs of the host in response to Leishmania infection, with the parasite capable of modulating host immune response, which may contribute to disease progression. We evaluated whether the co-expression of lncRNAs and their putative target mRNAs in primary cutaneous lesions of patients with ATL could be associated with the development of ML. Previously available public RNA-Seq data from primary skin lesions of patients infected with L. braziliensis was employed. We identified 579 mRNAs and 46 lncRNAs differentially expressed in the primary lesion that subsequently progressed to mucosal disease. Co-expression analysis revealed 1324 significantly correlated lncRNA-mRNA pairs. Among these, we highlight the positive correlation and trans-action between lncRNA SNHG29 and mRNA S100A8, both upregulated in the ML group. S100A8 and its heterodimeric partner S100A9 form a pro-inflammatory complex expressed by immune cells and seems to participate in host innate immune response processes of infection. These findings expand the knowledge of the Leishmania-host interaction and indicate that the expression of lncRNAs in the primary cutaneous lesion could regulate mRNAs and play roles in disease progression., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023 Elsevier B.V. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
24. Leishmaniasis epidemiology in endemic areas of metropolitan France and its overseas territories from 1998 to 2020
- Author
-
Pasquier, Grégoire, Demar, Magalie, Lami, Patrick, Zribi, Asma, Marty, Pierre, Buffet, Pierre, Desbois-Nogard, Nicole, Gangneux, Jean-Pierre, Simon, Stéphane, Blaizot, Romain, Couppié, Pierre, Thiebaut, Louis, Pratlong, Francine, Dedet, Jean-Pierre, Bastien, Patrick, Sterkers, Yvon, Ravel, Christophe, Lachaud, Laurence, Maladies infectieuses et vecteurs : écologie, génétique, évolution et contrôle (MIVEGEC), Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD [France-Sud])-Université de Montpellier (UM), Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], Hôpital Pasteur [Nice] (CHU), Centre d'infectiologie Necker-Pasteur [CHU Necker], Institut Pasteur [Paris] (IP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Cité (UPCité), CHU de la Martinique [Fort de France], École des Hautes Études en Santé Publique [EHESP] (EHESP), Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), and Chard-Hutchinson, Xavier
- Subjects
[SDV] Life Sciences [q-bio] ,Leishmaniasis, Mucocutaneous ,Infectious Diseases ,West Indies ,[SDV]Life Sciences [q-bio] ,Public Health, Environmental and Occupational Health ,Humans ,Leishmaniasis, Cutaneous ,France ,Leishmania infantum - Abstract
Background In France, leishmaniasis is endemic in the Mediterranean region, in French Guiana and to a lesser extent, in the French West Indies. This study wanted to provide an updated picture of leishmaniasis epidemiology in metropolitan France and in its overseas territories. Methodology/Principal findings Leishmaniasis cases were collected by passive notification to the French National Reference Centre for Leishmaniases (NRCL) in Montpellier from 1998 to 2020 and at the associated Centre in Cayenne (French Guiana) from 2003 to 2020. In metropolitan France, 517 autochthonous leishmaniasis cases, mostly visceral forms due to Leishmania infantum (79%), and 1725 imported cases (French Guiana excluded), mainly cutaneous leishmaniasis from Maghreb, were recorded. A slight decrease of autochthonous cases was observed during the survey period, from 0.48 cases/100,000 inhabitants per year in 1999 (highest value) to 0.1 cases/100,000 inhabitants per year in 2017 (lowest value). Conversely, imported cases increased over time (from 59.7 in the 2000s to 94.5 in the 2010s). In French Guiana, 4126 cutaneous and mucocutaneous leishmaniasis cases were reported from 2003 to 2020. The mean incidence was 103.3 cases per 100,000 inhabitants/year but varied in function of the year (from 198 in 2004 to 54 in 2006). In Guadeloupe and Martinique (French West Indies), only sporadic cases were reported. Conclusions/Significance Because of concerns about disease expansion and outbreaks in other Southern Europe countries, and leishmaniasis monitoring by the NRCL should be continued and associated with a more active surveillance.
- Published
- 2022
25. Clinical criteria for Mucosal Leishmaniasis diagnosis in rural South America
- Author
-
Jacob M. Bezemer, Kevin Meesters, Cristhian L. Naveda, Paulo R. L. Machado, Manuel Calvopiña, Mariska M. G. Leeflang, Henk D. F. H. Schallig, Henry J. C. de Vries, Dermatology, Epidemiology and Data Science, APH - Methodology, Medical Microbiology and Infection Prevention, AII - Infectious diseases, and APH - Personalized Medicine
- Subjects
Leishmania ,Leishmaniasis, Mucocutaneous ,Male ,Infectious Diseases ,Public Health, Environmental and Occupational Health ,Quality of Life ,Humans ,Infant ,Prospective Studies ,Ulcer - Abstract
Background Mucosal Leishmaniasis (ML), a neglected tropical disease caused by Leishmania parasites, impairs the quality of life of under-resourced populations in South America. If not treated promptly, this disease progresses to facial deformities and death. The low sensitivity of microscopy results and the unavailability of other accurate tests hamper the diagnosis. As clinical criteria are readily available in any setting, these may be combined in a syndromic algorithm, which in turn can be used as a diagnostic tool. We explore potential clinical criteria for a syndromic diagnostic algorithm for ML in rural healthcare settings in South America. Methodology/Principal findings The protocol for this systematic review was pre-registered in PROSPERO with the number: CRD42017074148. In patients with ML, described in case series identified through a systematic retrieval process, we explored the cumulative ML detection rates of clinical criteria. Participants: all patients with active mucosal disease from an endemic area in South America. Any original, non-treatment study was eligible, and case reports were excluded. PUBMED, EMBASE, Web of Science, SCIELO, and LILACS databases were searched without restrictions. The risk of bias was assessed with the JBI checklist for case series. We included 10 full texts describing 192 ML patients. Male gender had the highest detection rate (88%), followed by ulcer of the nasal mucosa (77%), age >15 (69%), and symptom duration >4 months (63%). Significance Within this selection of patients, we found that the male gender, ulcer of the nasal mucosa, age >15, and symptom duration >4 months lead to the highest detection rates. However, higher detection comes -naturally- with a higher rate of false positives as well. As we only included ML patients, this could not be verified. Therefore, the criteria that we found to be most promising should be validated in a well-designed prospective study.
- Published
- 2022
26. Are the clinical features of leprosy and American tegumentary leishmaniasis worse in patients with both diseases?
- Author
-
João Gabriel Luz, Amanda Gabriela Carvalho, Peter Steinmann, and Eliane Ignotti
- Subjects
Leishmaniasis, Mucocutaneous ,Mucocutaneous leishmaniasis ,Cross-Sectional Studies ,Cutaneous leishmaniasis ,Endemic Diseases ,Coinfection ,hemic and lymphatic diseases ,Leprosy ,Humans ,Leishmaniasis, Cutaneous ,Comorbidity ,Brazil - Abstract
This cross-sectional population-based study compared clinical features of leprosy and American tegumentary leishmaniasis (ATL) in patients diagnosed with both diseases (n=414) and in those diagnosed with only leprosy (n=27,790) or only ATL (n=24,357) in Mato Grosso State, which is a hyperendemic area for both diseases in Midwest Brazil. All new cases of leprosy and ATL reported in the area from 2008 to 2017 were included. Patients diagnosed with both diseases were identified by a probabilistic linkage procedure applied to leprosy and ATL databases of the national reporting system. The distribution of the frequency of clinical features between groups was compared by the chi-square test, followed by a multivariate logistic regression. Patients diagnosed with both leprosy and ATL presented higher odds of having nerve damage (OR: 1.34; 95% CI: 1.09–1.66) and leprosy reactions (OR: 1.35; 95% CI: 1.04–1.76) compared to patients diagnosed only with leprosy. Mucocutaneous leishmaniasis (OR: 2.29; 95% CI: 1.74–3.00) was more frequent among patients with both diagnoses when compared to patients who only had ATL. In conclusion, patients diagnosed with both leprosy and ATL present more severe clinical features of such diseases. Our data can be useful for designing health policies aimed at timely and integrated management of leprosy and ATL in co-endemic areas.
- Published
- 2022
27. Reprint of: Man with severe mucocutaneous leishmaniasis
- Author
-
Giselle Anelisse Pomalaza Cárdenas, Jhomara Estefani Rivas Travezaño, and Mijail Serafin Correa Chavez
- Subjects
Leishmaniasis, Mucocutaneous ,Male ,Humans ,General Medicine - Published
- 2022
28. Complementary exams in the diagnosis of american tegumentary leishmaniasis
- Author
-
Ciro Martins Gomes, Natália Aparecida de Paula, Orlando Oliveira de Morais, Killarney Ataíde Soares, Ana Maria Roselino, and Raimunda Nonata Ribeiro Sampaio
- Subjects
Dermatology ,Diagnosis ,Leishmaniasis, mucocutaneous ,Molecular biology ,Polymerase chain reaction ,Serologic tests ,RL1-803 - Abstract
The diagnosis of American Tegumentary Leishmaniasis is a difficult but essential task when considering the high toxicity profile of the drugs available. Since the discovery of its etiologic agent, numerous diagnostic tests have been developed. None of the tests available today can be considered as the gold standard, since they do not add enough accuracy for the disease detection. Good epidemiological and clinical knowledge of the disease are fundamental precepts of the dermatology practice and precede the rational use of existing diagnostic tests. In this article we aim, through extensive literature review, to recall fundamental concepts of any diagnostic test. Subsequently, based on this information, we will weave important comments about the characteristics of existing diagnostic tests, including immunological tests such as Montenegro's skin test, serology and detection of parasites by direct examination, culture or histopathology. Finally we will discuss the new technologies and options for the diagnosis of Cutaneous Leishmaniasis. The molecular biology technique is considered a promising tool, promoting the rapid identification of the species involved. We also aim to educate dermatologists about a disease with high morbidity and assist in its difficult recognition.
- Published
- 2014
- Full Text
- View/download PDF
29. Tongue Nodule as Primary Manifestation of American Cutaneous Leishmaniasis in an Immunocompetent Patient
- Author
-
Glauco Issamu Miyahara, Ana Carolina Prado-Ribeiro, Ana Maria Pires Soubhia, Lígia Lavezo Ferreira, Stelios Fikaris, Maria Clara Bertolini Botelho, Éder Ricardo Biasoli, Daniel Galera Bernabé, Universidade Estadual Paulista (Unesp), and Universidade de São Paulo (USP)
- Subjects
Leishmaniasis, Mucocutaneous ,Male ,0301 basic medicine ,Pathology ,medicine.medical_specialty ,Meglumine antimoniate ,Antiprotozoal Agents ,Case Reports ,Tongue Diseases ,Pathology and Forensic Medicine ,03 medical and health sciences ,0302 clinical medicine ,Tongue ,Fibrosis ,medicine ,Humans ,Oral mucosa ,Leishmaniasis ,Meglumine Antimoniate ,biology ,Tongue nodule ,business.industry ,Scar fibrosis ,Oral diagnosis ,Nodule (medicine) ,Middle Aged ,medicine.disease ,Leishmania ,biology.organism_classification ,030104 developmental biology ,medicine.anatomical_structure ,Oncology ,Otorhinolaryngology ,030220 oncology & carcinogenesis ,medicine.symptom ,Chronic Inflammatory Infiltrate ,business ,medicine.drug - Abstract
Made available in DSpace on 2021-06-25T10:47:43Z (GMT). No. of bitstreams: 0 Previous issue date: 2020-01-01 Leishmaniasis is a parasitic disease considered an endemic public health problem in developing countries, where it is a reportable disease. Isolated oral manifestation is rare, and its clinical manifestations are variable. In this paper we describe an unusual case of an immunocompetent patient, 57-year-old man with a painless reddish submucosal nodule located on the tongue dorsum. Microscopical analysis showed chronic inflammatory infiltrate with macrophages containing leishmania in cytoplasmic vacuoles. PCR assays confirmed the diagnosis and patient was treated with meglumine antimoniate for 30 days. Absence of the parasite was confirmed by PCR. Thirteen years after treatment, a scar fibrosis persisted on the tongue dorsum. The case reported reveals that leishmaniasis should be considered in the diagnosis of tongue nodules in immunocompetent patients. Oral Oncology Center School of Dentistry São Paulo State University (Unesp), 1193 José Bonifácio St Dental Oncology Service São Paulo State Cancer Institute (ICESP-FMUSP) University of São Paulo Medical School Department of Diagnosis and Surgery São Paulo State University (Unesp) School of Dentistry, 1193 José Bonifácio St Oral Oncology Center School of Dentistry São Paulo State University (Unesp), 1193 José Bonifácio St Department of Diagnosis and Surgery São Paulo State University (Unesp) School of Dentistry, 1193 José Bonifácio St
- Published
- 2020
30. Mucocutaneous Leishmaniasis due to Leishmania infantum Infection
- Author
-
Kai-Philipp Linse, Christian Bogdan, Holger A. Haenssle, and Ferdinand Toberer
- Subjects
Leishmaniasis, Mucocutaneous ,Humans ,Leishmaniasis, Cutaneous ,Leishmaniasis, Visceral ,Dermatology ,General Medicine ,Leishmania infantum - Abstract
is missing (Short communcation)
- Published
- 2022
31. In and out
- Author
-
Baijayanti, Jha, Marta, Reverte, Catherine, Ronet, Florence, Prevel, Florence D, Morgenthaler, Chantal, Desponds, Lon-Fye, Lye, Katherine L, Owens, Leonardo, Scarpellino, Lalit Kumar, Dubey, Amélie, Sabine, Tatiana V, Petrova, Sanjiv A, Luther, Stephen M, Beverley, and Nicolas, Fasel
- Subjects
Leishmania ,Leishmaniasis, Mucocutaneous ,Lymphatic System ,Neoplasms ,Humans ,Leishmania braziliensis - Abstract
The lymphatic system plays a crucial role in mounting immune response against intracellular pathogens, and recent studies have documented its role in facilitating tumor dissemination linked largely with cancer cells. However, in mucocutaneous leishmaniasis (MCL) caused by
- Published
- 2022
32. A Potential New Source of Therapeutic Agents for the Treatment of Mucocutaneous Leishmaniasis: The Essential Oil of
- Author
-
Carlos Vinicius Barros, Oliveira, Patric Anderson Gomes da, Silva, Saulo Relison, Tintino, Cathia Cecília, Coronel, Maria Celeste Vega, Gomez, Mírian, Rolón, Francisco Assis Bezerra da, Cunha, Maria Flaviana Bezerra, Morais-Braga, Henrique Douglas Melo, Coutinho, Abolghasem, Siyadatpanah, Polrat, Wilairatana, Jean Paul, Kamdem, Luiz Marivando, Barros, Antonia Eliene, Duarte, and Pedro Silvino, Pereira
- Subjects
Leishmaniasis, Mucocutaneous ,Mammals ,Lamiaceae ,Trypanosoma cruzi ,Antiprotozoal Agents ,Oils, Volatile ,Animals ,Chagas Disease ,Antioxidants - Abstract
Weeds are an important source of natural products; with promising biological activity. This study investigated the anti-kinetoplastida potential (in vitro) to evaluate the cytotoxicity (in vitro) and antioxidant capacity of the essential oil of
- Published
- 2022
33. The leishmaniases in Kenya: A scoping review.
- Author
-
Grifferty G, Shirley H, O'Brien K, Hirsch JL, Orriols AM, Amechi KL, Lo J, Chanda N, El Hamzaoui S, Kahn J, Yap SV, Watson KE, Curran C, Atef AbdelAlim A, Bose N, Cilfone AL, and Wamai R
- Subjects
- Female, Humans, Kenya epidemiology, Leishmania, Leishmaniasis, Cutaneous epidemiology, Leishmaniasis, Cutaneous complications, Leishmaniasis, Mucocutaneous, Leishmaniasis, Visceral drug therapy
- Abstract
Background: The leishmaniases are a group of four vector-borne neglected tropical diseases caused by 20 species of protozoan parasites of the genus Leishmania and transmitted through a bite of infected female phlebotomine sandflies. Endemic in over 100 countries, the four types of leishmaniasis-visceral leishmaniasis (VL) (known as kala-azar), cutaneous leishmaniasis (CL), mucocutaneous leishmaniasis (MCL), and post-kala-azar dermal leishmaniasis (PKDL)-put 1.6 billion people at risk. In Kenya, the extent of leishmaniasis research has not yet been systematically described. This knowledge is instrumental in identifying existing research gaps and designing appropriate interventions for diagnosis, treatment, and elimination., Methodology/principal Findings: This study used the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) methodology to determine the state of leishmaniases research in Kenya and identify research gaps. We searched seven online databases to identify articles published until January 2022 covering VL, CL, MCL, and/or PKDL in Kenya. A total of 7,486 articles were found, of which 479 underwent full-text screening, and 269 met our eligibility criteria. Most articles covered VL only (n = 141, 52%), were published between 1980 and 1994 (n = 108, 39%), and focused on the theme of "vectors" (n = 92, 34%). The most prevalent study types were "epidemiological research" (n = 88, 33%) tied with "clinical research" (n = 88, 33%), then "basic science research" (n = 49, 18%) and "secondary research" (n = 44, 16%)., Conclusion/significance: While some studies still provide useful guidance today, most leishmaniasis research in Kenya needs to be updated and focused on prevention, co-infections, health systems/policy, and general topics, as these themes combined comprised less than 4% of published articles. Our findings also indicate minimal research on MCL (n = 1, <1%) and PKDL (n = 2, 1%). We urge researchers to renew and expand their focus on these neglected diseases in Kenya., Competing Interests: The authors declare no competing interests., (Copyright: © 2023 Grifferty et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
- Published
- 2023
- Full Text
- View/download PDF
34. Publisher Correction: Multiple evolutionary lineages for the main vector of Leishmania guyanensis, Lutzomyia umbratilis (Diptera: Psychodidae), in the Brazilian Amazon
- Author
-
Ronildo Baiatone Alencar, Antônio Saulo Cunha-Machado, and Vera Margarete Scarpassa
- Subjects
Leishmaniasis, Mucocutaneous ,Science ,Leishmania guyanensis ,Gene Expression ,Zoology ,Biology ,Electron Transport Complex IV ,Rivers ,Animals ,Humans ,Psychodidae ,Phylogeny ,Multidisciplinary ,Amazon rainforest ,Genetic Variation ,Cytochromes b ,biology.organism_classification ,Publisher Correction ,Biological Evolution ,Insect Vectors ,Mitochondria ,Phylogeography ,Haplotypes ,Vector (epidemiology) ,Insect Proteins ,Lutzomyia umbratilis ,Medicine ,Female ,Brazil - Abstract
Lutzomyia umbratilis is the main vector of Leishmania guyanensis in the Brazilian Amazon and in neighboring countries. Previous biological and molecular investigations have revealed significant differences between L. umbratilis populations from the central Brazilian Amazon region. Here, a phylogeographic survey of L. umbratilis populations collected from nine localities in the Brazilian Amazon was conducted using two mitochondrial genes. Statistical analyses focused on population genetics, phylogenetic relationships and species delimitations. COI genetic diversity was very high, whereas Cytb diversity was moderate. COI genealogical haplotypes, population structure and phylogenetic analyses identified a deep genetic differentiation and three main genetic groups. Cytb showed a shallower genetic structure, two main haplogroups and poorly resolved phylogenetic trees. These findings, allied to absence of isolation by distance, support the hypothesis that the Amazon and Negro Rivers and interfluves are the main evolutionary forces driving L. umbratilis diversification. The main three genetic groups observed represent three evolutionary lineages, possibly species. The first lineage occurs north of the Amazon River and east of Negro River, where Le. guyanensis transmission is intense, implying that L. umbratilis is an important vector there. The second lineage is in the interfluve between north of Amazon River and west of Negro River, an area reported to be free of Le. guyanensis transmission. The third lineage, first recorded in this study, is in the interfluve between south of Amazonas River and west of Madeira River, and its involvement in the transmission of this parasite remains to be elucidated.
- Published
- 2021
35. Leishmania Viannia guyanensis, LRV1 virus and extracellular vesicles: a dangerous trio influencing the faith of immune response during muco-cutaneous leishmaniasis
- Author
-
Dario S. Zamboni and Martin Olivier
- Subjects
Leishmaniasis, Mucocutaneous ,0301 basic medicine ,Leishmaniavirus ,Immunology ,Virulence ,Virus ,Extracellular Vesicles ,03 medical and health sciences ,0302 clinical medicine ,Immune system ,Cutaneous leishmaniasis ,parasitic diseases ,medicine ,Animals ,Humans ,Immunology and Allergy ,Macrophage ,Leishmania guyanensis ,biology ,Leishmaniasis ,RNA virus ,medicine.disease ,Leishmania ,biology.organism_classification ,Virology ,3. Good health ,030104 developmental biology ,RNA ,030215 immunology - Abstract
Parasites of Leishmania genus have developed various strategies to overcome host immune response favoring its infection and development toward leishmaniasis. With an array of virulence factors, those parasites modify host macrophage signaling and functions. Depending of the species involved, visceral or cutaneous leishmaniasis will develop. Several years ago, Leishmania Viannia guyanensis that is naturally infected with the endosymbiotic virus Leishmania RNA Virus 1 was found to cause a particularly aggressive form of South-American mucocutaneous leishmaniasis. This virus, when co-transmitted with the parasite was shown to strongly modulate RNA sensors and NLRP3 inflammasome network that could explain in part the exacerbated skin pathology caused by this particular parasite. In this review, we will be discussing how this endosymbiotic virus-infected Leishmania in conjunction with Leishmania exosomes partner together to manipulate host immune response in their favor.
- Published
- 2020
36. Case Report: Mucosal Leishmaniasis in New York City
- Author
-
Daniel Eiras, Raymond L. Chai, Laura A. Kirkman, Henry W. Murray, and Daniel Caplivski
- Subjects
Leishmaniasis, Mucocutaneous ,Male ,Larynx ,medicine.medical_specialty ,Old World ,Leishmania tropica ,Phosphorylcholine ,030231 tropical medicine ,Antiprotozoal Agents ,Nasal Mass ,Leishmania braziliensis ,03 medical and health sciences ,0302 clinical medicine ,Amphotericin B ,Virology ,parasitic diseases ,Humans ,Medicine ,Mucosal leishmaniasis ,Aged ,biology ,Soft palate ,business.industry ,Pharynx ,Leishmaniasis ,Articles ,Middle Aged ,biology.organism_classification ,medicine.disease ,Dermatology ,Infectious Diseases ,medicine.anatomical_structure ,New York City ,Parasitology ,business - Abstract
The six previously reported civilian cases of mucosal leishmaniasis (ML) diagnosed in the United States have all represented imported New World ML. We describe two new patients with ML diagnosed in New York City—a Syrian immigrant with a nasal mass (Leishmania tropica), the first report of Old World ML in the United States, and an American ecologist who worked in Bolivia and had been treated for cutaneous infection 23 years before developing lesions (L. (Viannia) braziliensis) initially of the uvula, soft palate, and posterior pharynx and subsequently the larynx.
- Published
- 2020
37. Effectiveness and Safety of Amphotericin B Deoxycholate, Amphotericin B Colloidal Dispersion, and Liposomal Amphotericin B as Third-Line Treatments for Cutaneous and Mucocutaneous Leishmaniasis: A Retrospective Study
- Author
-
Mirian Yolanda Casas Vargas, Maria Fernanda Ordóñez Rubiano, Jairo Enrique Pérez Franco, and María Claudia Rodríguez Galvis
- Subjects
Leishmaniasis, Mucocutaneous ,medicine.medical_specialty ,Antiprotozoal Agents ,Leishmaniasis, Cutaneous ,Colombia ,Gastroenterology ,Cutaneous leishmaniasis ,Amphotericin B ,Virology ,Amphotericin B deoxycholate ,Internal medicine ,Humans ,Medicine ,Colloids ,Amphotericin B Colloidal Dispersion ,Adverse effect ,Retrospective Studies ,business.industry ,Retrospective cohort study ,Leishmaniasis ,Articles ,Mucocutaneous leishmaniasis ,medicine.disease ,Drug Combinations ,Infectious Diseases ,Parasitology ,business ,Deoxycholic Acid ,medicine.drug - Abstract
Cutaneous leishmaniasis (CL) and mucocutaneous leishmaniasis (MCL) are endemic diseases in America, especially in some countries such as Colombia. Among the therapeutic options is amphotericin B (AB). Nevertheless, its lipid-associated formulations have better safety profiles and effectiveness in other diseases, so far with no comparative studies in CL or MCL. We conducted a retrospective descriptive study describing the effectiveness and adverse effects of AB deoxycholate (ABD), AB colloidal dispersion (ABCD), and liposomal AB (LAB) as third-line treatments for CL and MCL. The effectiveness of LAB (88.5%) was greater than those of ABCD (66.6%) and ABD (80.8%). There were also fewer adverse effects in the LAB group (46.2%) than in the ABD (96.1%) and ABCD (80.9%) groups. LAB is an alternative for the treatment of CL and MCL in patients with therapeutic failure to first- and second-line drugs; findings suggest it might be less toxic and more effective than ABD and ABCD.
- Published
- 2020
38. Leishmania RNA virus-1 is similarly detected among metastatic and non-metastatic phenotypes in a prospective cohort of American Tegumentary Leishmaniasis
- Author
-
Braulio Mark Valencia, Rachel Lau, Ruwandi Kariyawasam, Marlene Jara, Ana Pilar Ramos, Mathilde Chantry, Justin T. Lana, Andrea K. Boggild, and Alejandro Llanos-Cuentas
- Subjects
Adult ,Leishmania ,Leishmaniasis, Mucocutaneous ,Male ,Leishmaniavirus ,RC955-962 ,prospective cohort ,Public Health, Environmental and Occupational Health ,Leishmaniasis, Cutaneous ,American Tegumentary Leishmaniasis ,Middle Aged ,Leishmania RNA virus-1 ,metastatic ,Cohort Studies ,non-metastatic ,Phenotype ,Infectious Diseases ,Arctic medicine. Tropical medicine ,Humans ,Prospective Studies ,Treatment Failure ,Public aspects of medicine ,RA1-1270 - Abstract
American Tegumentary Leishmaniasis (ATL) is an endemic and neglected disease of South America. Here, mucosal leishmaniasis (ML) disproportionately affects up to 20% of subjects with current or previous localised cutaneous leishmaniasis (LCL). Preclinical and clinical reports have implicated the Leishmania RNA virus-1 (LRV1) as a possible determinant of progression to ML and other severe manifestations such as extensive cutaneous and mucosal disease and treatment failure and relapse. However, these associations were not consistently found in other observational studies and are exclusively based on cross-sectional designs. In the present study, 56 subjects with confirmed ATL were assessed and followed out for 24-months post-treatment. Lesion biopsy specimens were processed for molecular detection and quantification of Leishmania parasites, species identification, and LRV1 detection. Among individuals presenting LRV1 positive lesions, 40% harboured metastatic phenotypes; comparatively 58.1% of patients with LRV1 negative lesions harboured metastatic phenotypes (p = 0.299). We found treatment failure (p = 0.575) and frequency of severe metastatic phenotypes (p = 0.667) to be similarly independent of the LRV1. Parasite loads did not differ according to the LRV1 status (p = 0.330), nor did Leishmanin skin induration size (p = 0.907) or histopathologic patterns (p = 0.780). This study did not find clinical, parasitological, or immunological evidence supporting the hypothesis that LRV1 is a significant determinant of the pathobiology of ATL.
- Published
- 2022
39. Avanços no tratamento da leishmaniose tegumentar do novo mundo nos últimos dez anos: uma revisão sistemática da literatura Advances in the treatment of cutaneous leishmaniasis in the new world in the last ten years: a systematic literature review
- Author
-
Olga Laura Sena Almeida and Jussamara Brito Santos
- Subjects
Leishmaniose cutânea ,Leishmaniose mucocutânea ,Terapêutica ,Leishmaniasis, cutaneous ,Leishmaniasis, mucocutaneous ,Treatment outcome ,Dermatology ,RL1-803 - Abstract
INTRODUÇÃO: O arsenal terapêutico contra a leishmaniose tegumentar é muito restrito. Os antimoniais pentavalentes permanecem como as drogas de escolha para seu tratamento há mais de 50 anos. Apesar da sua eficácia, necessita de injeções diárias, apresenta muitos efeitos colaterais e tempo de cura prolongado. OBJETIVO: Realizar uma revisão sistemática da literatura sobre os avanços no tratamento da leishmaniose tegumentar do novo mundo nos últimos dez anos. METODOLOGIA: Realizou-se em junho de 2009 uma busca eletrônica nas bases de dados Pubmed, LILACS e na biblioteca eletrônica Scielo. As palavras de busca em inglês foram: "cutaneous", "leishmaniasis" e "treatment". Foram incluÃdos apenas ensaios clÃnicos randomizados, duplo-cegos, placebo controlados. Utilizou-se a escala de Jadad para avaliar a qualidade dos estudos selecionados. RESULTADOS: Segundo os critérios de inclusão e exclusão, apenas 8 artigos foram selecionados. As drogas avaliadas nos estudos selecionados foram Glucantime®, miltefosine, imunoterapia, imiquimod, rhGM-CSF, pentoxifilina e paramomicina. CONCLUSÃO: Apesar de a leishmaniose tegumentar ser um importante problema de saúde pública, os dados publicados sobre o uso de novas drogas para o tratamento da leishmaniose tegumentar em nosso meio ainda são bastante limitadosINTRODUCTION: The therapeutic arsenal against cutaneous leishmaniasis is very limited. Pentavalent antimonial compounds have been the drugs of choice for treatment of this disease for over 50 years. Despite their effectiveness, these drugs require daily injections, have many side effects and present prolonged healing time. OBJECTIVE: To carry out a systematic literature review on the advances in the treatment of cutaneous leishmaniasis in the new world in the last ten years. METHODS: We conducted an electronic search on the Pubmed and LILACS database as well as on the SciELO electronic library in June 2009. The search words in English were: "cutaneous", "leishmaniasis" and "treatment". We included only randomized, double-blind and placebo controlled trials. We used the Jadad scale to assess the quality of the selected studies. RESULTS: According to the inclusion and exclusion criteria, only eight articles were selected. The drugs evaluated in the selected studies were glucantime®, miltefosine, immunotherapy, imiquimod, rhGM-CSF and pentoxifylline, and paromomycin. CONCLUSION: Although cutaneous leishmaniasis is a major public health issue, the published data on the use of new drugs for the treatment of cutaneous leishmaniasis in Brazil are still quite limited
- Published
- 2011
- Full Text
- View/download PDF
40. Biologia molecular aplicada às dermatoses tropicais Molecular biology in tropical dermatoses
- Author
-
Ana Maria Roselino
- Subjects
Biologia molecular ,Hanseníase ,Leishmaniose ,Leishmaniose mucocutânea ,Reação em cadeia da polimerase ,Polimorfismo genético ,Leishmaniasis ,Leishmaniasis, mucocutaneous ,Leprosy ,Molecular biology ,biology ,Polymerase chain reaction ,Polymorphism,genetic ,Dermatology ,RL1-803 - Abstract
São apresentados conceitos básicos sobre célula, código genético e síntese protéica, e sobre algumas técnicas de biologia molecular, tais como PCR, PCR-RFLP, seqüenciamento de DNA, RT-PCR e immunoblotting. São fornecidos protocolos de extração de nucleotídeos e de proteínas, como salting out no sangue periférico e métodos do fenol-clorofórmio e do trizol em tecidos. Seguem-se exemplos comentados da aplicação de técnicas de biologia molecular para o diagnóstico etiológico e pesquisa em dermatoses tropicais, com ênfase na leishmaniose tegumentar americana e hanseníase.Initially, basic concepts are presented concerning the cell, genetic code and protein synthesis, and some techniques of molecular biology, such as PCR, PCR-RFLP, DNA sequencing, RT-PCR and immunoblotting. Protocols of nucleotides and of proteins extraction are supplied, such as salting out in peripheral blood allied to phenol-chloroform and trizol methods in skin samples. To proceed, commented examples of application of those techniques of molecular biology for the etiologic diagnosis and for research in tropical dermatoses, with emphasis to American tegumentary leishmaniasis and leprosy are presented.
- Published
- 2008
- Full Text
- View/download PDF
41. Characterization of Differentially Abundant Proteins Among
- Author
-
Bárbara B, Esteves, Marcella N, Melo-Braga, Vladimir, Gorshkov, Thiago, Verano-Braga, Martin R, Larsen, Célia M F, Gontijo, Patricia F, Quaresma, and Helida M, Andrade
- Subjects
Antimony ,Leishmaniasis, Mucocutaneous ,Humans ,Leishmaniasis, Cutaneous ,Brazil ,Leishmania braziliensis ,Skin - Published
- 2021
42. A trespasser from a foreign land? A case report of primary mucosal leishmaniasis
- Author
-
Yoram Fleissig, Mary Dan-Gur, Ayelet Michael-Gayego, Alexander Maly, Rami Tabib, Charles L. Jaffe, and Maya Korem
- Subjects
Leishmaniasis, Mucocutaneous ,Infectious Diseases ,Mouth Mucosa ,Humans ,Leishmaniasis, Cutaneous ,Leishmaniasis ,Oral Ulcer ,Lip - Abstract
Background We report a clinically challenging and unusual case of L. donovani oral mucosal leishmaniasis. Case presentation Israeli resident with a former travel to central and North Africa, with no documented or prior cutaneous lesions presented with oral lesions of the maxillary gingiva and the upper lip. A delay in diagnosis and treatment have led to progression of the maxillary gingival lesions towards the hard palatal and the soft palate that could have potentially compromised the upper airway. Conclusions This case highlights the importance of early diagnosis of leishmaniasis in patients with oral lesions and the laboratory workup necessary to appropriately characterize and treat the disease.
- Published
- 2021
43. Human genetic polymorphism and Leishmaniasis
- Author
-
Kavita Bharati
- Subjects
Microbiology (medical) ,Leishmaniasis, Mucocutaneous ,Infectious Diseases ,Polymorphism, Genetic ,Genetics ,Humans ,Leishmaniasis, Cutaneous ,Leishmaniasis, Visceral ,Molecular Biology ,Microbiology ,Ecology, Evolution, Behavior and Systematics - Abstract
Leishmaniasis is a disease of the subtropical and tropical spheres of the earth and has various clinical manifestations. The different form of leishmaniasis includes cutaneous leishmaniasis, mucocutaneous leishmaniasis, most lethal visceral leishmaniasis and PKDL form. These different forms depend on many factors such as parasite and vector species, geographical, environmental conditions and population ethnicity. Host genetic factors have been widely investigated for their role in developing the disease in various infections. There are several reports on associations or resistance between candidate gene polymorphisms and the risk and outcome of Leishmania infection. Polymorphism in genes involved in both innate and adaptive immune systems, as well as genes of metabolic processes contributes to disease manifestation. The wide availability and advancement of molecular techniques permits to exploration of hereditary factors related to leishmaniasis. Many candidate gene studies were conducted on family-based and population to identify novel biomarkers for understanding disease pathogenesis pathways and possible drug targets. This comprehensive review presents an update on various human genes polymorphism that influence the outcome of different forms of Leishmania infection in endemic regions of the world. Various electronic databases were searched systematically for relevant publications and thoroughly analyzed. Most of the candidate gene studies were found with discrepancies in findings. Genetic and functional studies with adequate power are needed to validate the contribution of host genes in susceptibility or resistance towards Leishmania infection and understanding pathogenesis.
- Published
- 2021
44. The Paradox of a Phagosomal Lifestyle: How Innate Host Cell-Leishmania amazonensis Interactions Lead to a Progressive Chronic Disease
- Author
-
Matheus B. H. Carneiro and Nathan C. Peters
- Subjects
Leishmaniasis, Mucocutaneous ,Immunology ,Leishmaniasis, Cutaneous ,Review ,Adaptive Immunity ,Phagolysosome ,Leishmania braziliensis ,Host-Parasite Interactions ,Phagocytosis ,neutrophils ,Phagosomes ,Immunology and Allergy ,Animals ,Humans ,Leishmania major ,dendritic cells ,Pathogen ,Leishmania ,Innate immune system ,biology ,RC581-607 ,biology.organism_classification ,Acquired immune system ,Immunity, Innate ,macrophages ,Immune System ,Chronic Disease ,Leishmaniasis, Visceral ,phagolysosome ,Leishmania infantum ,Immunologic diseases. Allergy ,monocytes ,Leishmania amazonensis - Abstract
Intracellular phagosomal pathogens represent a formidable challenge for innate immune cells, as, paradoxically, these phagocytic cells can act as both host cells that support pathogen replication and, when properly activated, are the critical cells that mediate pathogen elimination. Infection by parasites of theLeishmaniagenus provides an excellent model organism to investigate this complex host-pathogen interaction. In this review we focus on the dynamics ofLeishmania amazonensisinfection and the host innate immune response, including the impact of the adaptive immune response on phagocytic host cell recruitment and activation.L. amazonensisinfection represents an important public health problem in South America where, distinct from otherLeishmaniaparasites, it has been associated with all three clinical forms of leishmaniasis in humans: cutaneous, muco-cutaneous and visceral. Experimental observations demonstrate that most experimental mouse strains are susceptible toL. amazonensisinfection, including the C57BL/6 mouse, which is resistant to other species such asLeishmania major,Leishmania braziliensisandLeishmania infantum. In general, the CD4+T helper (Th)1/Th2 paradigm does not sufficiently explain the progressive chronic disease established byL. amazonensis, as strong cell-mediated Th1 immunity, or a lack of Th2 immunity, does not provide protection as would be predicted. Recent findings in which the balance between Th1/Th2 immunity was found to influence permissive host cell availabilityviarecruitment of inflammatory monocytes has also added to the complexity of the Th1/Th2 paradigm. In this review we discuss the roles played by innate cells starting from parasite recognition through to priming of the adaptive immune response. We highlight the relative importance of neutrophils, monocytes, dendritic cells and resident macrophages for the establishment and progressive nature of disease followingL. amazonensisinfection.
- Published
- 2021
45. The stigma associated with cutaneous leishmaniasis (CL) and mucocutaneous leishmaniasis (MCL): A protocol for a systematic review.
- Author
-
Nuwangi H, Agampodi TC, Price HP, Shepherd T, Weerakoon KG, and Agampodi SB
- Subjects
- Animals, Humans, Quality of Life, Systematic Reviews as Topic, Meta-Analysis as Topic, Review Literature as Topic, Leishmaniasis, Mucocutaneous, Leishmaniasis, Visceral, Leishmaniasis, Cutaneous drug therapy
- Abstract
Leishmaniasis is a neglected tropical disease with three main clinical types; cutaneous leishmaniasis (CL), mucocutaneous leishmaniasis (MCL), and visceral leishmaniasis (VL). CL and MCL are considered to be highly stigmatizing due to potentially disfiguring skin pathology. CL and MCL-associated stigma are reported across the world in different contexts assimilating different definitions and interpretations. Stigma affects people with CL, particularly in terms of quality of life, accessibility to treatment, and psycho-social well-being. However, evidence on CL- and MCL-associated stigma is dispersed and yet to be synthesized. This systematic review describes the types, measurements, and implications of the stigma associated with CL and MCL and identifies any preventive strategies/interventions adopted to address the condition. This study was developed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocols (PRISMA-P) statement which is registered in the International Platform of Registered Systematic Review and Meta-analysis Protocols PROSPERO (ID- CRD42021274925). We will perform an electronic search in MEDLINE, Embase, Scopus, PubMed, EBSCO, Web of Science, Global Index Medicus, Trip, and Cochrane Library databases, and in Google Scholar, using a customized search string. Any article that discusses any type of CL- and/or MCL-associated stigma in English, Spanish and Portuguese will be included. Articles targeting veterinary studies, sandfly vector studies, laboratory-based research and trials, articles focusing only on visceral leishmaniasis, and articles on diagnostic or treatment methods for CL and MCL will be excluded. Screening for titles and abstracts and full articles and data extraction will be conducted by two investigators. The risk of bias will be assessed through specific tools for different study types. A narrative synthesis of evidence will then follow. This review will identify the knowledge gap in CL-associated stigma and will help plan future interventions., Competing Interests: The authors have declared that no competing interests exist., (Copyright: © 2023 Nuwangi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
- Published
- 2023
- Full Text
- View/download PDF
46. A urbanização da leishmaniose tegumentar americana no município de Campinas - São Paulo (SP) e região: magnitude do problema e desafios Urbanization of American Cutaneous Leishmaniasis in Campinas - Sao Paulo (SP) and region: problems and challenges
- Author
-
Lúcia Mensato Rebello da Silva and Paulo Rowilson Cunha
- Subjects
Epidemiologia ,Leishmaniose mucocutânea ,Psychodidae ,Zoonoses ,Epidemiology ,Leishmaniasis, mucocutaneous ,Dermatology ,RL1-803 - Abstract
FUNDAMENTOS - A leishmaniose tegumentar americana ocupa o segundo lugar entre as protozoonoses por vetores no Brasil. OBJETIVOS - Descrever a distribuição da doença na macrorregião de Campinas-SP e identificar as principais dificuldades em sua prevenção. MÉTODOS - A área estudada abrange 42 municípios. Os dados foram coletados no Sistema Nacional de Agravos e de Notificação do Grupo de Vigilância Epidemiológica, de 1998 a 2004, da Superintendência de Controle de Endemias, do Centro de Zoonoses e foi feita revisão da literatura. RESULTADOS - Foram registrados 458 casos, de caráter endêmico e com maior ocorrência em Campinas e Jundiaí. A doença predominava na área urbana (57%), no sexo masculino (62%) e acometia todas as faixas etárias. As espécies vetoras encontradas foram Lutzomyia intermedia sl, L. neivai, L. migonei, L. whitmani, L. fisheri, e L. pessoai. CONCLUSÕES - A leishmaniose tegumentar está distribuída amplamente na região (81% dos municípios estudados) e predominava na área urbana (57%). As dificuldades encontradas em seu controle foram a crescente adaptação do vetor ao peridomicílio, a multiplicidade dos fatores envolvidos na transmissão e a resposta insuficiente às medidas de controle atuais. O acompanhamento do ambiente e da doença, o diagnóstico e o tratamento precoces, a notificação compulsória e o seguimento dos casos, além de investimento em pesquisas, campanhas e ações diretas junto aos pacientes são importantes para o controle da doença.BACKGROUND - American cutaneous leishmaniasis (ACL) is ranked second among vector-transmitted zoonoses in Brazil. OBJECTIVES - This paper aims at verifying the distribution of this disease in Campinas-SP and surrounding region and to identify the main difficulties for preventive actions to this illness. METHODS - The Campinas area encloses 42 counties. Data from 1998 to 2004 were collected from the National System of Injuries and Notification in Campinas, from the Superintendence for the Control of Endemic Diseases and from the Center for Zoonoses. A literature review on the subject was performed. RESULTS - There were 458 reported endemic cases and most of them were found in the Campinas and Jundiaí metropolitan areas. ACL was predominant in urban areas (57%) and among males (62%). It was also observed in all age ranges, and among women and children. Among the known vector species, Lutzomyia intermedia sl, L. neivai, L. migonei, L. whitmani, L. fisheri and L. pessoai were reported. CONCLUSIONS - Four hundred and fifty eight cases were reported, in 81% of the studied counties. The main difficulties in ACL control have been increasing vector adaptation to the peri-urban environment; the multiplicity of factors involved in its transmission and poor results of current control measures over disease progression. More research efforts are needed to understand the environmental and epidemiological features involved in ACL endemic progression, early diagnosis and treatment. Also important is an efficient notification system, as well as improved patient follow-up and educational programs.
- Published
- 2007
- Full Text
- View/download PDF
47. The cure rate after different treatments for mucosal leishmaniasis in the Americas: A systematic review
- Author
-
Janaína de Pina Carvalho, Sarah Nascimento Silva, Mariana Lourenço Freire, Líndicy Leidicy Alves, Carolina Senra Alves de Souza, and Gláucia Cota
- Subjects
Antimony ,Leishmaniasis, Mucocutaneous ,Infectious Diseases ,Public Health, Environmental and Occupational Health ,Humans ,Pentoxifylline ,Systematic Reviews as Topic - Abstract
Background Mucosal or mucocutaneous leishmaniasis is the most severe form of tegumentary leishmaniasis due to its destructive character and potential damage to respiratory and digestive tracts. The current treatment recommendations are based on low or very low-quality evidence, and pentavalent antimonial derivatives remain strongly recommended. The aim of this review was to update the evidence and estimate the cure rate and safety profile of the therapeutic options available for mucosal leishmaniasis (ML) in the Americas. Methodology A systematic review was conducted in four different databases and by different reviewers, independently, to evaluate the therapeutic efficacy and toxicity associated with different treatments for ML. All original studies reporting cure rates in more than 10 patients from American regions were included, without restriction of design, language, or publication date. The risk of bias was assessed by two reviewers, using different tools according to the study design. The pooled cure rate based on the latest cure assessment reported in the original studies was calculated grouping all study arms addressing the same intervention. The protocol for this review was registered at the International Prospective Register of Systematic Reviews, PROSPERO: CRD42019130708. Principal findings Twenty-seven original studies from four databases fulfilled the selection criteria. A total of 1,666 patients with ML were treated predominantly with pentavalent antimonials in Brazil. Other interventions, such as pentamidine, miltefosine, imidazoles, aminosidine sulfate, deoxycholate and lipidic formulations of amphotericin B (liposomal, lipid complex, colloidal dispersion), in addition to combinations with pentoxifylline, allopurinol or sulfa were also considered. In general, at least one domain with a high risk of bias was identified in the included studies, suggesting low methodological quality. The pooled cure rate based on the latest cure assessment reported in the original studies was calculated grouping all study arms addressing the same intervention. It was confirmed that antimony is still the most used treatment for ML, with only moderate efficacy (possibly increased by combining with pentoxifylline). There is already evidence for the use of miltefosine for ML, with a cure rate similar to antimony, as observed in the only direct meta-analysis including 57 patients (OR: 1.2; 0.43–3.49, I2 = 0). It was possible to gather all descriptions available about adverse events reported during ML treatment, and the toxicity reflected the pattern informed in the manufacturers’ technical information. Conclusions This study provides an overview of the clinical experience in the Americas related to ML treatment and points out interventions and possible combinations that are eligible to be explored in future well-designed studies.
- Published
- 2022
48. Estudo clínico, epidemiológico e terapêutico de 402 pacientes com leishmaniose tegumentar americana atendidos no Hospital Universitário de Brasília, DF, Brasil Clinical, epidemiological and therapeuthic study of 402 patients with american cutaneous leishmaniasis attended at University Hospital of Brasilia, DF, Brazil
- Author
-
Roberto Querido Name, Karinne Tavares Borges, Lucas Souza Carmo Nogueira, João Herman Duarte Sampaio, Pedro Luiz Tauil, and Raimunda Nonata R. Sampaio
- Subjects
Leishmaniose mucocutânea ,Leishmaniasis, Mucocutaneous ,Dermatology ,RL1-803 - Abstract
FUNDAMENTOS: A leishmaniose tegumentar americana é doença em expansão no Brasil. A região Centro-Oeste é hoje a terceira em incidência e a primeira em crescimento da doença. OBJETIVOS: Avaliar pacientes com leishmaniose tegumentar americana atendidos no Hospital Universitário de Brasília, quanto a aspectos clinicoepidemiológicos e resposta ao tratamento com antimonial pentavalente. MÉTODOS: Estudo do tipo série de casos de 402 pacientes, segundo sexo, idade, ocupação, procedência, formas clínicas, métodos de diagnóstico, tratamento com antimonial pentavalente e efeitos colaterais, no período de 1/1/1994 a 28/2/2003. O acompanhamento foi de um ano pós-tratamento. RESULTADOS: Predomínio de homens, lavradores, de 20 a 39 anos, com a forma cutânea. A eficácia do antimonial foi maior em pacientes com forma cutânea tratados até seis meses depois do início dos sintomas, e em pacientes do sexo feminino (diferenças estatisticamente significativas na análise multivariada). O mesmo ocorreu para pacientes com forma mucocutânea, mas sem diferença estatística significante. Alterações eletrocardiográficas foram mais freqüentes no grupo tratado com 20mg SbV/kg/dia por 30 dias em relação ao tratado por 20 dias. Eosinofilia ocorreu em 17,5% dos casos. CONCLUSÕES: Tratamento precoce, sexo feminino e a forma cutânea apresentaram índices mais elevados de cura. Alterações do eletrocardiograma aumentaram com o tempo de tratamento com antimoniais. A eosinofilia como efeito colateral ao uso do antimonial merece maior investigação.BACKGROUND: American cutaneous leishmaniasis is a disease with high prevalence and incidence in Brazil. The Brazilian Central-Western Region currently holds the third largest incidence and the first growth rate of this disease in the country. OBJECTIVES: To evaluate clinical, epidemiological and treatment features of patients with American cutaneous leishmaniasis seen at the University Hospital of Brasília. METHOD: A case series study with 402 patients was carried out, spanning the period between January 1st, 1994 and February 28th, 2003. The following variables were studied: sex, age, occupation, state of origin, clinical features, diagnostic techniques, treatment with pentavalent antimony and side effects. Follow-up was one year after the end of treatment. RESULTS: The predominant group of patients was composed by male rural laborers who presented mainly the cutaneous form of the illness. The greatest efficacy of the antimony was observed in patients presenting the cutaneous form treated up to six months after the onset of symptoms, and in females in general (both differences were statistically significant in multivariate analysis). The early treatment of the mucocutaneous form also presented better results, although not statistically significant. Electrocardiographical alterations were more frequent in the group of patients receiving a 20mg SbV/Kg/day for a 30-day schedule than those with the same dosage for 20 days. Eosinophilia was found in 17.5%. CONCLUSIONS: Early treatment, female gender and cutaneous form presented higher levels of cure. Electrocardiographic changes rose as time of treatment was increased. The remarkable report of eosinophilia as a side effect of N-methylglucamine deserves further investigation.
- Published
- 2005
- Full Text
- View/download PDF
49. Recurrent cutaneous leishmaniasis Leishmaniose recidiva cútis
- Author
-
Ciro Martins Gomes, Fabiana dos Santos Damasco, Orlando Oliveira de Morais, Carmen Déa Ribeiro de Paula, and Raimunda Nonata Ribeiro Sampaio
- Subjects
Leishmaniose ,Leishmaniose mucocutânea ,Pentoxifilina ,Recidiva ,Terapêutica ,Leishmaniasis ,Leishmaniasis, mucocutaneous ,Pentoxifylline ,Recurrence ,Therapeutics ,Dermatology ,RL1-803 - Abstract
We present a case of an 18-year-old male patient who, after two years of inappropriate treatment for cutaneous leishmaniasis, began to show nodules arising at the edges of the former healing scar. He was immune competent and denied any trauma. The diagnosis of recurrent cutaneous leishmaniasis was made following positive culture of aspirate samples. The patient was treated with N-methylglucamine associated with pentoxifylline for 30 days. Similar cases require special attention mainly because of the challenges imposed by treatment.Paciente do sexo masculino, 18 anos. Dois anos após tratamento insuficiente para leishmaniose tegumentar americana, apresentou, na mesma localização, lesão formada por cicatriz atrófica central e nódulos verrucosos na periferia. Era imunocompetente, hígido e negava qualquer trauma local. O diagnóstico de leishmaniose recidiva cutis foi feito através de cultura do aspirado da lesão. Realizou tratamento com N-metilglucamina (20mgSbV/kg/dia) associado à pentoxifilina (1200mg/dia) durante 30 dias alcançando cura clínica. Os casos semelhantes requerem atenção diferenciada pela dificuldade ao tratamento.
- Published
- 2013
50. Treatment of Bolivian Leishmania braziliensis Cutaneous and Mucosal Leishmaniasis
- Author
-
Jaime Soto, Patricia Gutiérrez, Paula Soto, David Paz, Eduardo Cayhuara, Carmen Molina, Mia Sánchez, and Jonathan Berman
- Subjects
Leishmaniasis, Mucocutaneous ,Bolivia ,Infectious Diseases ,Meglumine Antimoniate ,Treatment Outcome ,Virology ,Antiprotozoal Agents ,Humans ,Leishmaniasis, Cutaneous ,Parasitology ,Leishmania braziliensis ,Research Article - Abstract
Although infection with Leishmania braziliensis is perhaps the key reason to treat New World cutaneous leishmaniasis (CL) and mucosal leishmaniasis (ML), the total literature contains relatively few reported cases. With the aim of supplementing the meager clinical information available, we searched the records of Jorochito (Dermatology) Hospital, Bolivia, for the years 1999–2020 and identified treatment records for 1,696 naive CL patients and 355 naive ML patients. Because follow-up was poor for this real-world treatment experience in the developing world, only 255 CL patients (15%) and 114 ML patients (32%) attended follow-up at Hospital. We therefore engaged in an Active Search for “lost” patients, located a further 542 CL patients (32%) and 142 ML patients (44%), thus eventually accomplished follow up on 697 CL patients (41%) and 256 ML patients (72%). Granular adverse event data derived from hospital records is listed for the 902 CL and 86 ML patients administered Glucantime intramuscularly, the 401 CL and 202 ML patients administered Glucantime intravenously, and the 163 CL and 89 ML patients administered miltefosine orally. Efficacy was obtained from hospital records for patients seen at hospital and from patient recall communicated by telephone for the patients found in the Active Search. The overall CL cure rate was 508 of 697 CL patients (73%) with follow-up: intramuscular Glucantime—196/293 (67%); intravenous Glucantime—90/126 (71%); intralesional Glucantime—34/54 (63%); oral miltefosine—52/69 (75%). The overall ML cure rate was 161 of 256 ML patients (63%) with follow-up: intramuscular Glucantime—26/48 (54%); intravenous Glucantime—66/104 (63%); intravenous amphotericin B deoxycholate—19/35 (54%); oral miltefosine—50/71 (70%). We offer this extensive adverse event and efficacy experience as useful guides for clinicians presented with a L. braziliensis infection. The cure rates also illustrate the quandary of New World CL and ML chemotherapy: sufficiently high to be useful but nevertheless needing augmentation with new agents.
- Published
- 2021
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.